Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | May 14, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | Ainos, Inc. | |
Entity Central Index Key | 0001014763 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | No | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 142,240,594 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2021 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Incorporation, State or Country Code | TX | |
Entity File Number | 0-20791 |
Balance Sheets
Balance Sheets - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Assets | ||
Cash and cash equivalents | $ 9,377 | $ 22,245 |
Inventory | 0 | 3,024 |
Prepaid expense and other current assets | 32,890 | 51,144 |
Total current assets | 42,267 | 76,413 |
Patents, net | 177,051 | 180,628 |
Property and equipment, net | 2,921 | 3,249 |
Total assets | 222,239 | 260,290 |
Liabilities and Stockholders' Equity (Deficit) | ||
Accounts payable and accrued expenses | 348,548 | 145,567 |
Notes payable - related party | 236,854 | 0 |
Convertible notes payable related party | 915,016 | 953,001 |
Total current liabilities | 1,500,418 | 1,098,568 |
Total liabilities | 1,500,418 | 1,098,568 |
Stockholders' equity (deficit) | ||
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at March 31, 2021 and December 31, 2020 | 0 | 0 |
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 42,066,172 and 42,066,172 at March 31, 2021 and December 31, 2020, respectively | 420,662 | 420,662 |
Additional paid-in capital | 5,055,420 | 4,961,315 |
Accumulated deficit | (6,754,261) | (6,220,255) |
Total stockholders’ equity (deficit) | (1,278,179) | (838,278) |
Total liabilities and stockholders’ equity (deficit) | $ 222,239 | $ 260,290 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 42,066,172 | 42,066,172 |
Common stock, shares outstanding (in shares) | 42,066,172 | 42,066,172 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
Revenues | $ 2,121 | $ 15,200 |
Cost of revenues | (1,249) | (10,806) |
Gross margin | 872 | 4,394 |
Operating expenses: | ||
Selling, general and administrative expenses | 522,981 | 380,268 |
Total operating expenses | 522,981 | 380,268 |
Operating loss | (522,109) | (375,874) |
Other income (expense) | ||
Interest income (expense), net | (11,897) | (1,005) |
Net income (loss) | (534,006) | (376,879) |
Less: Net Income attributable to non-controlling interests | 0 | 0 |
Net loss attributable to common shareholders | $ (534,006) | $ (376,879) |
Basic and diluted net loss per average share available to common shareholders (in dollars per share) | $ (0.01) | $ (0.01) |
Weighted average common shares outstanding – basic and diluted (in shares) | 42,066,172 | 40,516,351 |
Statements of Stockholders' Equ
Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) | Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total |
Balance (in shares) at Dec. 31, 2019 | 0 | 40,516,351 | |||
Balance at Dec. 31, 2019 | $ 0 | $ 405,164 | $ 4,207,786 | $ (4,769,632) | $ (156,682) |
Warrant expense | 9,496 | 9,496 | |||
Option expense | 90,688 | 90,688 | |||
Net loss | (376,879) | (376,879) | |||
Balance (in shares) at Mar. 31, 2020 | 0 | 40,516,351 | |||
Balance at Mar. 31, 2020 | $ 0 | $ 405,164 | 4,307,970 | (5,146,511) | (433,377) |
Balance (in shares) at Dec. 31, 2020 | 0 | 42,066,172 | |||
Balance at Dec. 31, 2020 | $ 0 | $ 420,662 | 4,961,315 | (6,220,255) | (838,278) |
Warrant expense | 3,417 | 3,417 | |||
Option expense | 90,688 | 90,688 | |||
Net loss | (534,006) | (534,006) | |||
Balance (in shares) at Mar. 31, 2021 | 0 | 42,066,172 | |||
Balance at Mar. 31, 2021 | $ 0 | $ 420,662 | $ 5,055,420 | $ (6,754,261) | $ (1,278,179) |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Statement of Cash Flows [Abstract] | ||
Net cash used in operating activities | $ (119,482) | $ (115,712) |
Cash flows from financing activities | ||
Proceeds from related party note | 0 | 102,844 |
Net cash used in financing activities | 0 | 102,844 |
Net change in cash | (119,482) | (12,868) |
Cash and cash equivalents at beginning of period | 409,039 | 22,245 |
Cash and cash equivalents at end of period | 289,557 | 9,377 |
Supplemental Cash Flow Information | ||
Cash paid for interest | 0 | 0 |
Cash paid for income taxes | 0 | 0 |
Non-Cash Transactions | ||
Stock issued for accrued liabilities | 0 | 0 |
Stock issued for advances from investors | 0 | 0 |
Conversion of debt to common stock | $ 0 | $ 0 |
Note 1 - Organization and Busin
Note 1 - Organization and Business | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Organization and Business | Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the "Company") is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. The Company is a Texas corporation which was formed in 1984. |
Note 2 - General
Note 2 - General | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
General | The Company primarily operates through three divisions: Pharmaceutical, Medical and Consumer. The Pharmaceutical division leverages our extensive library of clinical research by applying the Company's experience in the use of low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Company seeks to engage in patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing technology to treat metabolism related diseases such as type-1 and type-2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize a unique liposomal delivery system. The Company currently has offices in the United States and Taiwan. The Company operates in Taiwan under the name AMARILLO BIOSCIENCES, INC. TAIWAN BRANCH ( 美商康華全球生技股 份有限公司 台灣分公司 ). |
Note 3 - Basis of Presentation
Note 3 - Basis of Presentation | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Basis of Presentation | The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021. |
Note 4 - Financial Condition
Note 4 - Financial Condition | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Financial Condition | These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved sustained operating income, and its operations are funded primarily from related-party convertible debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability. The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern. |
Note 5 - Common Stock
Note 5 - Common Stock | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Common Stock | The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On March 31, 2021, a total of 51,383,130 shares of common stock were either issued (42,066,172), reserved for conversion of convertible debt to stock (4,032,919), issuance to two Company officers and consultants as compensation (174,422), and held for future exercise of nonqualified options and warrants (5,109,617). We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future. |
Note 6 - Convertible Notes Paya
Note 6 - Convertible Notes Payable and Other Related Party Notes Payable | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Convertible Notes Payable and Other Related Party Notes Payable | Convertible Notes Payable and Other Related Party Notes Payable. Note #. Conversion Rate Interest Rate March 31, 2021 December 31, 2020 Note 1 - Chen $ 0.1680 0.75 % $ 114,026 $ 114,026 Note 2 - Chen $ 0.1875 0.65 % $ 262,500 $ 262,500 Note 3.19 - Chen $ 0.2500 1.85 % $ 39,620 $ 39,620 Note 4.19 - Chen $ 0.2500 1.61 % $ 14,879 $ 14,879 Note 5.19 – i2China $ 0.2500 1.85 % $ 16,000 $ 16,000 Note 6.20 - Chen $ 0.2500 1.85 % $ 216,600 $ 216,600 Note 7.20 - Chen $ 0.2500 1.60 % $ 23,366 $ 23,366 Note 8.20a – i2China $ 0.2500 1.85 % $ 48,000 $ 48,000 Note 8.20b – i2China $ 0.2500 1.85 % $ 84,000 $ 84,000 Note 9.21 - Chen N/A 0.13 % $ 236,854 $ 134,010 Note 10.21 – Chen $ 0.2500 1.85 % $ 59,025 - Note 11 – i2China $ 0.2500 1.85 % $ 37,000 - Total Convertible Notes (including accrued Interest) – Related Party $ 1,151,870 $ 953,001 Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China Management Group, LLC, the Company’s management consultant, elected to defer cash compensation during a period of development and fundraising. The parties received convertible promissory notes in consideration of the deferrals. On January 1, 2020, the Company issued Note #6.20 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $216,600, the maximum amount of cash compensation that could be deferred for 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $216,600 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty. On January 1, 2020, the Company issued Note #7.20 to Dr. Stephen T. Chen for deferred reimbursement of expenses advanced on behalf of the Company for $30,000, the maximum amount of reimbursable expense that could be deferred. Actual reimbursable expenses deferred is $23,366. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.60%. The note is an advancing note with a maximum limit of $30,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance against the Note, until Maturity, the amount submitted on a completed and approved reimbursement form along with documentation of the amount to be advanced. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Companuy’s common voting stock. All shares issued are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the Note in whole or in part at any time without penalty. On January 1, 2020, the Company issued Note #8.20 for deferred compensation to i2China Management Group, LLC in the amount of $48,000, the maximum amount of cash compensation that could be deferred in 2020. The Note is payable on January 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $48,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $4,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share. On January 1, 2021, the Company issued Note #10.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $59,025. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR short-term rate of 1.85%. The note is an advancing note with a maximum limit of $59,025 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock. __________ 1 Applicable Federal Rate - On January 1, 2021, the Company issued Note #11 for deferred compensation to i2China Management Group, LLC in the amount of $37,000. The Note is payable on April 1, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note is an advancing note with a maximum limit of $37,000 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $11,000 on the last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share. The notes are unsecured and are due on demand. All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen are related party notes. |
Note 7 - Other Related Party Tr
Note 7 - Other Related Party Transactions | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Other Related Party Transactions | Other than the aforementioned convertible notes activity, there were no related party transactions that occurred during the period from January 1, 2021 to March 31, 2021. |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Subsequent Events | On April 1, 2021, the Company issued Note #11.21 for deferred compensation to Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, in the amount of $18,050. The Note is payable on May 1, 2021, or on demand and bears interest at the AFR [1] short-term rate of 1.85%. The note is an advancing note with a maximum limit of $18,050 whereby the Company promises to repay the aggregate Principal Amount advanced to date up to the stated maximum amount at Maturity. The Company may request and the payee shall advance up to $9,025 on the 15th and last day of each month until the note matures. The Note may be convertible in whole or in part at a conversion price of $0.25 per share into the Company’s common voting stock. On April 15, 2021, the Company On April 27, 2021, the Company issued Note #12.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $15,000. The Note is payable on October 27, 2021, or on demand and bears interest at the AFR1 short-term rate of 1.85%. The note has a maximum limit of $15,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity. The Note may be convertible in whole or in part at a conversion price of $0.20 per share. On April 28, 2021, Mr. Chia-Hsi Chen resigned as the Company’s Chief Operating Officer as of April 28, 2021 as reported by the Form 8-K filed by the Company with the SEC on May 3, 2021, attached hereto as Exhibit 99.3 and which is incorporated by reference. On May 5, 2021, the Company issued Note #13.21 for a short-term loan for working capital purposes from Ainos, Inc., a Cayman Islands Corporation in the amount of $20,000. The Note is payable on November 5, 2021, or on demand and bears interest at the Applicable Federal Rate (short-term rate) of 1.85%. The note has a maximum limit of $20,000 whereby the Company promises to repay the aggregate Principal Amount to date up to the stated maximum amount at Maturity. The Note may be convertible in whole or in part at a conversion price of $0.20 per share. Notes #11.21, #12.21, and #13.21 All shares issued on conversion are to be restricted subject to Rule 144 promulgated under the U.S. Securities Act of 1933. The Company may prepay the notes in whole or in part at any time without penalty. The convertible notes due to Dr. Chen and Ainos, Inc., a Cayman Islands Corporation are related party notes. |
Note 6 - Convertible Notes Pa_2
Note 6 - Convertible Notes Payable and Other Related Party Notes Payable (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Convertible Debt | Note #. Conversion Rate Interest Rate March 31, 2021 December 31, 2020 Note 1 - Chen $ 0.1680 0.75 % $ 114,026 $ 114,026 Note 2 - Chen $ 0.1875 0.65 % $ 262,500 $ 262,500 Note 3.19 - Chen $ 0.2500 1.85 % $ 39,620 $ 39,620 Note 4.19 - Chen $ 0.2500 1.61 % $ 14,879 $ 14,879 Note 5.19 – i2China $ 0.2500 1.85 % $ 16,000 $ 16,000 Note 6.20 - Chen $ 0.2500 1.85 % $ 216,600 $ 216,600 Note 7.20 - Chen $ 0.2500 1.60 % $ 23,366 $ 23,366 Note 8.20a – i2China $ 0.2500 1.85 % $ 48,000 $ 48,000 Note 8.20b – i2China $ 0.2500 1.85 % $ 84,000 $ 84,000 Note 9.21 - Chen N/A 0.13 % $ 236,854 $ 134,010 Note 10.21 – Chen $ 0.2500 1.85 % $ 59,025 - Note 11 – i2China $ 0.2500 1.85 % $ 37,000 - Total Convertible Notes (including accrued Interest) – Related Party $ 1,151,870 $ 953,001 |
Note 5 - Common Stock (Details
Note 5 - Common Stock (Details Narrative) - shares | 3 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | |
Stockholders' equity (deficit) | ||
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Stock issued during period | 42,066,172 | |
Shares reserved for conversion of convertible debt to stock | 4,032,919 | |
Stock issued as compensation | 174,422 | |
Shares held for furutre exercise of noqualified options and warrants | 5,109,617 |
Note 6 - Convertible Notes Pa_3
Note 6 - Convertible Notes Payable - Related Party (Details Textual) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Convertible Notes Payable, Total | $ 1,151,870 | $ 953,001 |
Note 1 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 114,026 | 114,026 |
Debt Instrument, Interest Rate, Stated Percentage | 0.75% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.168 | |
Note 2 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 262,500 | 262,500 |
Debt Instrument, Interest Rate, Stated Percentage | 0.65% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.1875 | |
Note 3 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 39,620 | 39,620 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 4 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 14,879 | 14,879 |
Debt Instrument, Interest Rate, Stated Percentage | 1.61% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 5 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 16,000 | 16,000 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 6 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 216,600 | 216,600 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 7 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 23,366 | 23,366 |
Debt Instrument, Interest Rate, Stated Percentage | 1.60% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 8a | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 48,000 | 48,000 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 8b | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 84,000 | 84,000 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 9 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 236,854 | 134,010 |
Debt Instrument, Interest Rate, Stated Percentage | 0.13% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0 | |
Note 10 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 59,025 | 0 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | |
Note 11 | ||
Notes Payable, Convertible, Related Parties, Classified Current | $ 37,000 | $ 0 |
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | |
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 |
Note 6 - Convertible Notes Pa_4
Note 6 - Convertible Notes Payable - Related Party - Convertible Notes Payable, Outstanding (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Convertible Notes Payable [Abstract] | ||
Convertible note payable | $ 915,016 | $ 953,001 |